Rasagiline – 100 mg

Brand:
Cayman
CAS:
136236-51-6
Storage:
-20
UN-No:
Non-Hazardous - /

Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC50 = 4.43 nM for rat brain enzyme).{24081} It is selective for MAO-B over MAO-A (IC50 = 412 nM for rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 µM.{24079} Rasagiline inhibits rat brain MAO-B in vivo (ED50 = 0.1 mg/kg).{24081} It reduces cerebral edema in a mouse model of traumatic brain injury.(24079} Rasagiline (0.1 mg/kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson’s disease.{61047} Formulations containing rasagiline have been used in the treatment of Parkinson’s disease.  

 

SKU: - Category:

Description

An inhibitor of MAO-B (IC50 = 4.43 nM for rat brain enzyme); selective for MAO-B over MAO-A (IC50 = 412 nM for rat brain enzyme); inhibits rat brain MAO-B in vivo (ED50 = 0.1 mg/kg); reduces cerebral edema in a mouse model of traumatic brain injury; reduces cortical and hippocampal levels of full-length and soluble APP in rats and mice at 0.1 mg/kg; reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson’s disease


Formal name: (1R)-2,3-dihydro-N-2-propyn-1-yl-1H-inden-1-amine

Synonyms:  (R)-(+)-Rasagiline

Molecular weight: 171.2

CAS: 136236-51-6

Purity: ≥95%

Formulation: A solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cell Biology|Cell Death|Apoptosis||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease||Research Area|Neuroscience|Neuroprotection